Taysha Gene Therapies Shareholders Back Governance and Leadership
TipRanks (Tue, 2-Jun 5:44 PM ET)
TipRanks (Mon, 1-Jun 7:40 AM ET)
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 6-May 8:00 AM ET)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 1-May 4:05 PM ET)
Globe Newswire (Wed, 29-Apr 8:00 AM ET)
Globe Newswire (Mon, 27-Apr 5:21 PM ET)
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 19-Mar 8:00 AM ET)
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Market Chameleon (Thu, 2-Oct 5:54 AM ET)
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies trades on the NASDAQ stock market under the symbol TSHA.
As of June 3, 2026, TSHA stock price declined to $5.46 with 525,298 million shares trading.
TSHA has a beta of 2.35, meaning it tends to be more sensitive to market movements. TSHA has a correlation of 0.14 to the broad based SPY ETF.
TSHA has a market cap of $1.57 billion. This is considered a Small Cap stock.
Last quarter Taysha Gene Therapies reported $0 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-758,330 and missed earnings estimates by -$.02.
In the last 3 years, TSHA traded as high as $7.30 and as low as $.50.
The top ETF exchange traded funds that TSHA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
TSHA has outperformed the market in the last year with a price return of +96.1% while the SPY ETF gained +28.6%. TSHA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.5% and +5.3%, respectively, while the SPY returned +10.2% and +2.9%, respectively.
TSHA support price is $5.46 and resistance is $5.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TSHA shares will trade within this expected range on the day.
